Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

Papp, Kim; Soliman, Ahmed M.; Done, Nicolae; Carley, Christopher; Wirtz, Esteban Lemus; Puig, Luís

doi:10.1007/s13555-021-00550-8

Cited by 7 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the small number of clinical trials and systematic reviews, case series have been included, despite the fact that the evaluation of efficacy and effectiveness in them is very limited. 19–30 The studies that have been evaluated are: 8 clinical trials with high evidence, 19 , 20 , 23–26 , 28 , 29 3 case series, one prospective, 21 and 2 retrospective, 22 , 27 of which the evidence is of low quality, and a cohort study of medium evidence quality. 30 …”

Section: Resultsmentioning

confidence: 99%

“… At week 52, improvements in patients treated with RZB compared with those treated with UST were sustained for PSS, DLQI, and EQ-5D-5L. High Papp et al 20 Design: Clinical Trial Aim : To evaluate the impact of RZB withdrawal on HRQL measured by DLQI. Because DLQI was not measured beyond week 16 in IMMhance, a machine learning predictive model for DLQI was developed.…”

Section: Resultsmentioning

confidence: 99%

“…Eight of the twelve included studies are clinical trials, 2 , 19 , 20 , 23–26 , 28 and the rest are case series, 21 , 22 , 27 and a cohort study. 30 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

Gracia‐Cazaña¹,

Bernal-Masferrer²,

Morales-Callaghan³

et al. 2023

CCID

View full text Add to dashboard Cite

Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of Th17. RZB has proved their efficacy and their safety compared to anti-TNF. However, studies that assess and compare the improvement in other secondary PROs such as the patient’s quality of life are still scarce. Health-related quality of life (HRQoL) is the sum of physical health, well-being, and participation; it defines the functional effect of a disease or its treatment and how it is perceived by the patient. The objective of this paper is to analyze the literature on the impact of treatment with RZB on the quality of life of patients with PSO and their psychological well-being. A bibliographic search was carried out to identify all the papers published from July 2015 to June 1, 2022, on RZB treatment in psoriasis and its impact on health-related quality of life and psychological well-being, finally twenty articles have been evaluated in full text, of which 8 were excluded because they did not meet the inclusion criteria. Risankizumab has shown not only to have very relevant data on effectiveness and safety, but all of this is associated with an improvement in quality of life related to health and psychological well-being measured on generic and specific quality of life scales, both in pivotal trials, ad hoc analysis, and data in real clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

Gracia‐Cazaña¹,

Bernal-Masferrer²,

Morales-Callaghan³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…Recently, an ML model accurately predicted the Dermatology Quality of Life Index for psoriasis patients stopping risankizumab [45], a similar ML technology was used to build a highly effective biomarker for predicting the progression of alopecia areata to alopecia totalis or alopecia universalis [46]. Furthermore, a multicenter prospective open-label pilot study was lately conducted referring to treating psoriatic patients with secukinumab.…”

Section: Dermatologymentioning

confidence: 99%

New Opportunities and Challenges for Health Professionals in the era of Artificial Intelligence – Review

Warchoł

Adam

Zając

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose:Modern medical knowledge has grown to a vastness incomprehensible for a single health professional to learn and accommodate. The usage of modern information technologies comes to help, one of them being artificial intelligence, a branch of computer science aimed at developing solutions to perform tasks similar to the human brain, but more efficient and complex, without actual human intervention. The goal of 805 this review is to provide reader with the knowledge how artificial intelligence is applied in various branches of medicine. Brief description of the state of knowledge:In the fields of infectious diseases, including COVID-19 diagnostics, radiology, dermatology and surgery, works lean toward the statement, which suspect application of AI is beneficial for medical practitioners. Programs help to develop statistical models for virus spreading and the creation of antiviral solutions. The radiological application involves the analysis of images to aid radiologists in diagnosing certain features, similarly to dermatology, where eg. AI can identify malignancy of skin nevi.In the department of surgery, predictive algorithms can help in choosing operation methods and improve outcomes.Conclusions: Usage of AI assistance in the medical field has proven to be successful, but it is yet to be commonly encountered in everyday work. Programs need to be further developed and made more approachable to users without expertise in the IT field. AI may also prove useful in the process of education of health professionals.

show abstract

“…The authors underscore the need for prospective clinical trials to validate the use of ML models to predict outcomes. Recently, a ML model accurately predicted the Dermatology Quality of Life Index for patients with psoriasis withdrawing from risankizumab ( 35 ), while similar ML technology was used to build a highly accurate biomarker predicting the progression of alopecia areata to alopecia totalis or alopecia universalis ( 36 ). A multicenter prospective open label pilot study was recently conducted treating psoriasis patients with secukinumab.…”

mentioning

confidence: 99%

Editorial: The Emerging Role of Artificial Intelligence in Dermatology

et al. 2021

View full text Add to dashboard Cite

Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

Cited by 7 publications

References 38 publications

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

New Opportunities and Challenges for Health Professionals in the era of Artificial Intelligence – Review

Editorial: The Emerging Role of Artificial Intelligence in Dermatology

Contact Info

Product

Resources

About